SCHEMBL2024397

SCHEMBL2024397

O=C1c2ccccc2CN1Cc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
MEN1 O00255 4/20 0.60
DRD3 P35462 2/20 0.55
DRD2 P14416 1/20 0.55
DRD5 P21918 1/20 0.55
HDAC1 Q13547 2/20 0.55
KCNH2 Q12809 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
KDM4E B2RXH2 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
SIRT1 Q96EB6 1/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ACHE P22303 1/20 0.50
CES2 O00748 1/20 0.49
BCHE P06276 1/20 0.49
CES1 P23141 1/20 0.49
MMP2 P08253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31252762 1.00 KMT2A (0.60) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL29630944 0.88 KMT2A (0.60) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL1466305 0.88 KMT2A (0.60) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL5240140 0.86 DRD3 (0.58) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL2026453 0.86 HDAC1 (0.60) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL2024836 0.86 KMT2A (0.66) KMT2AMEN1HDAC1HDAC7KDM4E
SCHEMBL31667008 0.86 KMT2A (0.62) KMT2AMEN1HDAC1HDAC7KDM4E
SCHEMBL2024433 0.86 KMT2A (0.59) KMT2AMEN1DRD3DRD2DRD5
SCHEMBL31666975 0.86 HDAC1 (0.60) KMT2AMEN1HDAC1HDAC7KDM4E
SCHEMBL27991792 0.86 KMT2A (0.62) KMT2AMEN1HDAC1HDAC7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024061340-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-03-28 WO disclosed
WO-2019174279-A1 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2019-09-19 WO disclosed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
EP-1778634-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2007-05-02 EP disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 KMT2A 3975/4885MEN1 2588/4885DRD3 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.